What Envera does

Envera is an industrial microbiology company founded in 2004 by Michael L. Matheny that develops and manufactures proprietary spore-forming Bacillus bacteria products and custom fermentation services for B2B customers across eight vertical markets: Animal Care, Aquaculture, Bioremediation, Consumer Products, Custom Fermentation, Industrial & Institutional, Plant Health, and Wastewater. The company's underlying technology rests on a proprietary culture collection of more than 5,000 isolated bacterial strains (including patented low-temperature strains cryopreserved at -80°C), genetic sequencing and single-cell genomics for strain isolation, proprietary biological assays for screening desirable traits, and industrial-scale fermentation capacity comprising one 5,600L and three 9,400L bioreactors integrated into a Siemens-based unified process automation system built by Applied Control Engineering (ACE). Manufacturing, fermentation, R&D labs, and administration are housed in a 50,000+ sq ft FDA-registered, GMP-compliant facility in West Chester, Pennsylvania producing bulk concentrates in liquid, powder, water-soluble packet, and Bioblock formats.

Envera operates exclusively as a B2B bulk concentrate supplier with no public e-commerce or self-serve pricing; all transactions are quote-based, with minimum order quantities customized to customer needs and packaging ranging from fiber drums and plastic pails to totes and super sacks. Revenue is generated through two streams: bulk microbial product sales (where customers further blend or dilute Envera's concentrates into their own finished formulations, deliberately avoiding competition with those customers) and custom fermentation services spanning strain selection, scalable production, analytical lab testing, and multi-phase QC. Value-added services include Product Analysis & Development, Education & Training, and Regulatory Support for worldwide agency filings. Envera ships globally to every continent including Antarctica, with named customer markets in the USA, Canada, Brazil, Thailand, Vietnam, and France.

Since November 2017, Envera has operated under Lesaffre Group ownership (majority stake acquired in 2017, full acquisition completed in 2023). Lesaffre, a family-owned French fermentation company founded in 1853 with over 10,000 employees, acquired Envera to advance its position as a global fermentation expert; Envera operates as a closely linked but independent affiliate, supplying both Lesaffre affiliates and external customers. The company holds granted patents in the US, Europe, Mexico, Australia, and Eurasia covering dried spore germinative compounds, bacterial spore compositions, and novel Bacillus strains.

Name

Envera

Legal name

Envera LLC, LIC

Website

https://envera.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

11–50 employees

Short description

Envera is an industrial microbiology company that develops and manufactures proprietary spore-forming Bacillus bacteria products and custom fermentation services for B2B customers across animal care, aquaculture, wastewater, plant health, bioremediation, consumer, and industrial cleaning markets, operating as a Lesaffre Group affiliate from West Chester, Pennsylvania.

Ownership category

akta.pro rank

Headquarters

HQ city

West Chester

HQ country

United States

HQ region

North America

Offices3 records

Markets served

Revenue model

1. Bulk Microbial Product Sales: Envera manufactures and sells highly concentrated microbial-based products in various forms (liquids, powders, water soluble packets, solid technology/Bioblocks) to B2B customers. Products are typically designed to be further blended or diluted by customers, creating a bulk concentrate business model that avoids competition with customers' finished products. Sales supported by full-service partnership including strain selection, product development, quality assurance, regulatory assistance, and sales/marketing support.
2. Custom Fermentation Services: Envera provides custom fermentation services for clients, optimizing growth conditions and downstream process parameters for large-scale production. Services include analytical lab testing, scalable production, and multi-phase QC systems. Envera works with clients from strain selection through to mass production and regulatory navigation.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Envera is an industrial microbiology company that develops and manufactures proprietary spore-forming Bacillus bacteria-based products for aquaculture, animal nutrition (direct-fed microbials), wastewater treatment, environmental bioremediation, plant health, and consumer/institutional cleaning applications. The company also offers custom contract fermentation and manufacturing services to external clients, leveraging its proprietary culture collection and large-scale GMP-compliant production capabilities.

Product overview

Envera is an industrial microbiology company that provides biological products and custom fermentation services based on naturally occurring microorganisms. The company operates as a bulk, business-to-business supplier offering proprietary spore-forming bacteria (primarily Bacillus species) through multiple product markets including Animal Care, Aquaculture, Bioremediation, Consumer Products, Custom Fermentation, Industrial & Institutional, Plant Health, and Wastewater treatment. Their core products include beneficial bacteria strains, direct-fed microbials (DFMs), and wastewater treatment solutions sold as powders, liquids, water soluble packets (WSPs), and Bioblocks. Envera also provides complementary services including Product Analysis & Development, Education & Training, and Regulatory Support. The company has a culture collection of over 5,000 isolated bacterial strains and operates industrial-scale fermentation capabilities with bioreactors for large-scale commercial production.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• 99% reduction in biological oxygen demand (BOD) after 5 days in food processing wastewater treated with Envera's solution vs. control
• +5 more outcomes

Segments8 records

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

One partnership is on record.

• Applied Control Engineering, Inc. (ACE)coreImplementation/ SI/ Consulting PartnerACE, a Siemens Solution Partner, worked with Envera to commission, upgrade, and integrate every piece of equipment in Envera's fermentation facility into a single unified process automation system. All automation was custom-built by ACE. This project decreased time from R&D to production and greatly improved product yield, providing immeasurable efficiency improvements for growth and innovation.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• BioGaia: Swedish probiotics specialist focused on Lactobacillus and Bifidobacterium strains for human and animal applications. Comparable to Envera's strain isolation, proprietary culture library, and DFM business model.
• Lallemand Inc. Canadian-owned global yeast and bacteria producer with animal nutrition, brewing, and bio-ingredients divisions. Closely comparable to Envera's bulk B2B Bacillus-based cultures business and similar custom fermentation service model.
• Bio-Cat Inc. US-based probiotics and enzyme manufacturer producing custom microbial blends for animal nutrition, food, and environmental applications. Closely comparable in scale, product format, and B2B bulk model.
• Lallemand Animal Nutrition: Specialty division of Lallemand focused on probiotic DFMs, yeast derivatives, and silage inoculants for livestock. Directly comparable to Envera's animal care/DFM product line and bulk B2B distribution.

Broad incumbents

• Novonesis (Novozymes + Chr. Hansen): World's largest industrial microbiology platform formed from Novozymes and Chr. Hansen. Overlaps with Envera across enzymes, cultures, probiotics, and animal/health biosolutions, though at much larger scale and broader portfolio.
• Kerry Group: Global taste and nutrition company with fermentation-derived ingredients, cultures, and food biotechnology capabilities. Comparable to Envera's human-grade probiotic and food ingredient offerings.
• dsm-firmenich: Global nutrition and health company with substantial probiotics, animal nutrition, and specialty food ingredients divisions. Comparable to Envera's DFM and food-grade probiotic offerings, with significantly broader scope.
• IFF Health & Biosciences (formerly DuPont N&B): Major ingredient and biosciences producer with cultures, enzymes, probiotics, and animal nutrition offerings. Overlaps with Envera particularly in industrial microbial cultures and animal probiotics.

Emerging players

• AB Enzymes: Industrial enzyme manufacturer with fermentation capabilities serving food, feed, and industrial markets. Partial overlap with Envera's fermentation platform and industrial biotech applications.

Others

• Lesaffre (parent reference): Envera's parent company and global fermentation leader; included as a reference for the technical and commercial context that frames Envera's bacterial cultures business within the broader yeast and fermentation industry.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/EnveraLLC
• LinkedInlinkedin.com/company/envera

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Envera